They will decide whether you should stop taking Keytruda. They may also recommend creams or antihistamines to help with your rash and itchiness. Skin reactions are a common side effect of Keytruda ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Her skin hypopigmentation (discoloration of the skin) began as a minor issue in 2022 while taking a different treatment, Lenvima with Keytruda, which resulted ... increased sun sensitivity and severe ...

Common adverse events (AEs) associated with Keytruda include fatigue, diarrhea, rash, and nausea. For patients who receive Keytruda in combination with chemotherapy, the most common AEs included ...

The study has been testing the efti/Keytruda combination as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma with negative PD-L1 expression. The Australian ...

That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...